Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial

<p>Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD).</p> <p>This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in moderate-to-severe AD patients with or without previous systemic treatments....

詳細記述

保存先:

書誌詳細
第一著者:	Qingchun Diao (5751701) (author)
その他の著者:	Ruiling Jia (22654733) (author), Min Li (12799) (author), Peng Zhao (128233) (author), Fang Lu (45632) (author), Qin Zhang (58638) (author), Chunzhu Ning (22680917) (author), Juan Long (4017317) (author), Jiajia Li (184267) (author), Yan Huang (46805) (author), Yuyi Wang (462133) (author)
出版事項:	2025
主題:	Medicine Pharmacology Biotechnology Science Policy Biological Sciences not elsewhere classified Ivarmacitinib moderate-to-severe atopic dermatitis previous systemic treatments efficacy safety
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

このレコードへの初めてのコメントを付けませんか!

Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial

類似資料